Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies

Susanne Hansen; Marianne Søndergaard; Anna von Bülow; Anne-Sofie Bjerrum; Johannes Schmid; Linda M Rasmussen; Claus R Johnsen; Truls Ingebrigtsen; Kjell Erik Julius Håkansson; Sofie Lock Johansson; Maria Bisgaard; Karin Dahl Assing; Ole Hilberg; Charlotte Ulrik; Celeste Porsbjerg

doi:10.1016/j.chest.2023.10.046

Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies

Susanne Hansen, Marianne Søndergaard, Anna von Bülow, Anne-Sofie Bjerrum, Johannes Schmid, Linda M Rasmussen, Claus R Johnsen, Truls Ingebrigtsen, Kjell Erik Julius Håkansson, Sofie Lock Johansson, Maria Bisgaard, Karin Dahl Assing, Ole Hilberg, Charlotte Ulrik, Celeste Porsbjerg

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

Abstract

BACKGROUND: The development of novel targeted biologic therapies for severe asthma has provided an opportunity to consider remission as a new treatment goal.

RESEARCH QUESTION: How many patients with severe asthma treated with biologic therapy achieve clinical remission, and what predicts response to treatment?

STUDY DESIGN AND METHODS: The Danish Severe Asthma Register is a nationwide cohort including all adult patients receiving biologic therapy for severe asthma in Denmark. This observational cohort study defined "clinical response" to treatment following 12 months as a ≥ 50% reduction in exacerbations and/or a ≥ 50% reduction in maintenance oral corticosteroid dose, if required. "Clinical remission" was defined by cessation of exacerbations and maintenance oral corticosteroids, as well as a normalization of lung function (FEV 1 > 80%) and an Asthma Control Questionnaire-6 score ≤ 1.5 following 12 months of treatment.

RESULTS: Following 12 months of treatment, 104 (21%) of 501 biologic-naive patients had no response to treatment, and 397 (79%) had a clinical response. Among the latter, 97 (24%) fulfilled the study criteria of clinical remission, corresponding to 19% of the entire population. Remission was predicted by shorter duration of disease and lower BMI in the entire population of patients treated with biologic therapy.

INTERPRETATION: Clinical response was achieved in most adult patients initiating biologic therapy, and clinical remission was observed in 19% of the patients following 12 months of treatment. Further studies are required to assess the long-term outcome of achieving clinical remission with biologic therapy.

Original language	English
Journal	Chest
Volume	165
Issue	2
Pages (from-to)	253-266
Number of pages	14
ISSN	0012-3692
DOIs	https://doi.org/10.1016/j.chest.2023.10.046
Publication status	Published - Feb 2024

Keywords

biologics
epidemiology
remission
severe asthma

Access to Document

10.1016/j.chest.2023.10.046

Cite this

Hansen, S., Søndergaard, M., von Bülow, A., Bjerrum, A.-S., Schmid, J., Rasmussen, L. M., Johnsen, C. R., Ingebrigtsen, T., Håkansson, K. E. J., Johansson, S. L., Bisgaard, M., Assing, K. D., Hilberg, O., Ulrik, C., & Porsbjerg, C. (2024). Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies. Chest, 165(2), 253-266. https://doi.org/10.1016/j.chest.2023.10.046

@article{ae31292319b94ea68223b9b39266e288,

title = "Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies",

abstract = "BACKGROUND: The development of novel targeted biologic therapies for severe asthma has provided an opportunity to consider remission as a new treatment goal.RESEARCH QUESTION: How many patients with severe asthma treated with biologic therapy achieve clinical remission, and what predicts response to treatment?STUDY DESIGN AND METHODS: The Danish Severe Asthma Register is a nationwide cohort including all adult patients receiving biologic therapy for severe asthma in Denmark. This observational cohort study defined {"}clinical response{"} to treatment following 12 months as a ≥ 50% reduction in exacerbations and/or a ≥ 50% reduction in maintenance oral corticosteroid dose, if required. {"}Clinical remission{"} was defined by cessation of exacerbations and maintenance oral corticosteroids, as well as a normalization of lung function (FEV 1 > 80%) and an Asthma Control Questionnaire-6 score ≤ 1.5 following 12 months of treatment. RESULTS: Following 12 months of treatment, 104 (21%) of 501 biologic-naive patients had no response to treatment, and 397 (79%) had a clinical response. Among the latter, 97 (24%) fulfilled the study criteria of clinical remission, corresponding to 19% of the entire population. Remission was predicted by shorter duration of disease and lower BMI in the entire population of patients treated with biologic therapy.INTERPRETATION: Clinical response was achieved in most adult patients initiating biologic therapy, and clinical remission was observed in 19% of the patients following 12 months of treatment. Further studies are required to assess the long-term outcome of achieving clinical remission with biologic therapy.",

keywords = "biologics, epidemiology, remission, severe asthma",

author = "Susanne Hansen and Marianne S{\o}ndergaard and {von B{\"u}low}, Anna and Anne-Sofie Bjerrum and Johannes Schmid and Rasmussen, {Linda M} and Johnsen, {Claus R} and Truls Ingebrigtsen and H{\aa}kansson, {Kjell Erik Julius} and Johansson, {Sofie Lock} and Maria Bisgaard and Assing, {Karin Dahl} and Ole Hilberg and Charlotte Ulrik and Celeste Porsbjerg",

year = "2024",

month = feb,

doi = "10.1016/j.chest.2023.10.046",

language = "English",

volume = "165",

pages = "253--266",

journal = "Chest",

issn = "0012-3692",

publisher = "AMER COLL CHEST PHYSICIANS",

number = "2",

}

Hansen, S, Søndergaard, M, von Bülow, A, Bjerrum, A-S , Schmid, J, Rasmussen, LM, Johnsen, CR, Ingebrigtsen, T, Håkansson, KEJ, Johansson, SL, Bisgaard, M, Assing, KD, Hilberg, O, Ulrik, C & Porsbjerg, C 2024, 'Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies', Chest, vol. 165, no. 2, pp. 253-266. https://doi.org/10.1016/j.chest.2023.10.046

TY - JOUR

T1 - Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies

AU - Hansen, Susanne

AU - Søndergaard, Marianne

AU - von Bülow, Anna

AU - Bjerrum, Anne-Sofie

AU - Schmid, Johannes

AU - Rasmussen, Linda M

AU - Johnsen, Claus R

AU - Ingebrigtsen, Truls

AU - Håkansson, Kjell Erik Julius

AU - Johansson, Sofie Lock

AU - Bisgaard, Maria

AU - Assing, Karin Dahl

AU - Hilberg, Ole

AU - Ulrik, Charlotte

AU - Porsbjerg, Celeste

PY - 2024/2

Y1 - 2024/2

N2 - BACKGROUND: The development of novel targeted biologic therapies for severe asthma has provided an opportunity to consider remission as a new treatment goal.RESEARCH QUESTION: How many patients with severe asthma treated with biologic therapy achieve clinical remission, and what predicts response to treatment?STUDY DESIGN AND METHODS: The Danish Severe Asthma Register is a nationwide cohort including all adult patients receiving biologic therapy for severe asthma in Denmark. This observational cohort study defined "clinical response" to treatment following 12 months as a ≥ 50% reduction in exacerbations and/or a ≥ 50% reduction in maintenance oral corticosteroid dose, if required. "Clinical remission" was defined by cessation of exacerbations and maintenance oral corticosteroids, as well as a normalization of lung function (FEV 1 > 80%) and an Asthma Control Questionnaire-6 score ≤ 1.5 following 12 months of treatment. RESULTS: Following 12 months of treatment, 104 (21%) of 501 biologic-naive patients had no response to treatment, and 397 (79%) had a clinical response. Among the latter, 97 (24%) fulfilled the study criteria of clinical remission, corresponding to 19% of the entire population. Remission was predicted by shorter duration of disease and lower BMI in the entire population of patients treated with biologic therapy.INTERPRETATION: Clinical response was achieved in most adult patients initiating biologic therapy, and clinical remission was observed in 19% of the patients following 12 months of treatment. Further studies are required to assess the long-term outcome of achieving clinical remission with biologic therapy.

AB - BACKGROUND: The development of novel targeted biologic therapies for severe asthma has provided an opportunity to consider remission as a new treatment goal.RESEARCH QUESTION: How many patients with severe asthma treated with biologic therapy achieve clinical remission, and what predicts response to treatment?STUDY DESIGN AND METHODS: The Danish Severe Asthma Register is a nationwide cohort including all adult patients receiving biologic therapy for severe asthma in Denmark. This observational cohort study defined "clinical response" to treatment following 12 months as a ≥ 50% reduction in exacerbations and/or a ≥ 50% reduction in maintenance oral corticosteroid dose, if required. "Clinical remission" was defined by cessation of exacerbations and maintenance oral corticosteroids, as well as a normalization of lung function (FEV 1 > 80%) and an Asthma Control Questionnaire-6 score ≤ 1.5 following 12 months of treatment. RESULTS: Following 12 months of treatment, 104 (21%) of 501 biologic-naive patients had no response to treatment, and 397 (79%) had a clinical response. Among the latter, 97 (24%) fulfilled the study criteria of clinical remission, corresponding to 19% of the entire population. Remission was predicted by shorter duration of disease and lower BMI in the entire population of patients treated with biologic therapy.INTERPRETATION: Clinical response was achieved in most adult patients initiating biologic therapy, and clinical remission was observed in 19% of the patients following 12 months of treatment. Further studies are required to assess the long-term outcome of achieving clinical remission with biologic therapy.

KW - biologics

KW - epidemiology

KW - remission

KW - severe asthma

UR - http://www.scopus.com/inward/record.url?scp=85183485889&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2023.10.046

DO - 10.1016/j.chest.2023.10.046

M3 - Journal article

C2 - 37925144

SN - 0012-3692

VL - 165

SP - 253

EP - 266

JO - Chest

JF - Chest

IS - 2

ER -

Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this